nanotech investing Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247
nanotech investing Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy
nanotech investing Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress
nanotech investing Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference
nanotech investing Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Market One Minute Feature on BNN Bloomberg: Omega Pacific Resources Drills to Expand Gold Discovery in BC's Toodoggone
QIMC Engages Global Seismic Processing Leader Earth Signal to Advance Nova Scotia Hydrogen and Helium Multi-Gas Pilot Production Pathway
